Abstract-Bioresorbable lms can serve simultaneously as anatomic support structures and as drug delivery platforms. In the present study, bioresorbable PLLA lms containing dexamethasone were developed through solution processing. The effect of processing parameters on the lm morphology and the resulting mechanical properties was studied. A model describing the structuring of these lms is suggested. Generally, the solvent evaporation rate determines the kinetics of drug and polymer crystallizationand thus, both the mode of drug dispersion in the polymer and the resulting mechanical properties. Two types of structured lms were studied: (1) a polymer lm with drug located on its surface, obtained due to drug skin formation accompanied by a later polymer core formation; and (2) a polymer lm with small drug particles and crystals distributed within the bulk, obtained by parallel solidi cation of the two components. A prototypical application of these lms is an expandable biodegradable support structure (stent), which we have developed. This stent demonstrated good initial mechanical properties. The lm structure has only a minor effect on the stent radial compression strength, but more signi cantly affects the tensile mechanical properties.
INTRODUCTION
Polylactic acid (PLA) is one of the most important biodegradable polymers, being used in a wide range of clinical applications, such as devices for orthopaedic ¤ To whom correspondence should be addressed. E-mail: meital.zilberman@email.swmed.edu surgery [1 -5] , cardiovascular surgery [6, 7] , sutures [8] , and as drug delivering implants [9 -12] .
The semi-crystalline poly(L-lactic acid) (PLLA) is well known for the rst three mentioned applications, where high mechanical strength and toughness are required. This polymer can be formed into lms, tubes and matrices using standard processing techniques such as molding, extrusion, solvent casting and spinning [8] .
The most popular types of drug delivery systems based on PLLA are microparticles, implants and bers [9] . Various melt processing techniques, such as compression molding, injection molding and extrusion have been utilized to fabricate PLLA based implants loaded with bioactive agents. However, the limiting factor in case of melt processing of implants for drug delivery is the heat stability of the active agent [9] . Solution casting of polymers is a well known method for preparation of PLA-based lms. In order to incorporate drugs by this method, the polymer is dissolved in a solvent and mixed with the drug, prior to casting. Dexamethasone is a steroidal anti-in ammatory drug. It has been incorporated into bioresorbable polymer microparticles for various uses [13] [14] [15] . In the current research PLA lms loaded with dexamethasone were developed through solution processing. Polymer/ dexamethasone lms are reported in this paper for the rst time.
The currently-used metal stents support blood vessels, airway and other structures, but require a removal operation and do not provide drug delivery [16] [17] [18] . A bioresorbable stent that would support such conduits as the neonatal trachea, until the airway matures thereafter being totally resorbed, would be ideal. We developed a novel expandable PLLA based stent, prepared from a solution-cast PLLA based lm. Dexamethasone is incorporated into this lm based stent to permit its controlled local release. In addition to its anti-in ammatory activity, dexamethasone has been demonstrated to inhibit brotic response. Therefore the addition of this drug may be helpful in the prevention of proliferative reactions, such as an induced stenosis.
The current research focuses on the effects of lm processing parameters on the morphology and the resulting mechanical properties of the lms. In addition, a model describing the structuring of these lms is suggested. The basic mechanical properties of stents, prepared in this fashion are described. 
EXPERIMENTAL

Materials
Film preparation
Polymer lms (0.12-0.15 mm thickness) consisting of poly lactic acid and dexamethasone were prepared by a three step solution processing method: (a) Components were mixed in chloroform at room temperature until polymer dissolution. A constant (polymer C drug) quantity was chosen for all experiments.
In most experiments DM content was 2 wt%. In others, contents of 3, 5, and 10 wt% were used. For each polymer/ drug composition two kinds of solution were prepared, diluted and concentrated. The solubility of DM in chloroform at room temperature is approximately 1 mg ml ¡1 .
Dilute solution.
A dilute solution was prepared by using a relatively large volume of chloroform (concentration range of the polymer: 0.01-0.02 g ml ¡1 ; concentration range of DM: 2 £ 10 ¡4 -10 ¡3 g ml ¡1 ). Both DM and poly lactic acid were totally dissolved.
Concentrated solution.
A concentrated solution was prepared by using a relatively small volume of chloroform (concentration range of the polymer: 0.05-0.1 g ml ¡1 ; concentration range of DM: 10 ¡3 -5 £ 10 ¡3 g ml ¡1 ). In this solution the polymer was totally dissolved, while the DM powder was only broken into small particles (aggregates), which yielded an opaque solution. (b) Solution casting into a Petri dish and solvent drying under atmospheric pressure at room temperature. Two solvent evaporation rates were used: a relatively slow rate of 2-5 ml h ¡1 and a relatively fast rate of 10-20 ml h ¡1 .
(c) Isothermal heat treatment at 90 ± C for 1 h in a vacuum oven.
Morphological characterization
Films. Polarized light microscopy (LM) was performed using an Olympus BHS compound microscope and a Nikon Diathot inverted light microscope. Transmission electron microscopy (TEM) of ultramicrotomed samples was performed using a Jeol 1200 EX II at an accelerating voltage of 80 kV. High-resolution scanning electron microscopy (HRSEM) of cryogenically fractured surfaces was performed using a Leo Gemini-982, at an accelerating voltage of 1 kV.
Dexamethasone powder. Scanning electron microscopy (SEM) was performed for the drug powders, using a Jeol JSM 840 A at an accelerating voltage of 10 kV. The SEM samples were gold-sputtered prior to observation.
Thermal analysis
Melting temperature (T m ), heat of fusion (1H m ), and degree of crystallinity (%C ) were determined by differential thermal analysis using an indium calibrated TA Instruments DSC 2010 differential scanning calorimeter (DSC). The measurements were carried out on 10 mg samples under N 2 atmosphere, heating the samples from 30 to 250 ± C (above their melting points). The analysis was performed with a TA Universal Analysis software.
The degree of crystallinity, %C, was calculated by the following relationship:
where 1H m and 1H F are the heats of fusion of the sample (a semicrystalline material) and the perfect crystal, respectively. For PLLA 1H F D 93:6 J g ¡1 [19] .
Mechanical properties measurements
The mechanical properties of the lms were measured at room temperature in unidirectional tension at a rate of 10 mm min ¡ (ASTM D 882-97), using a Universal Testing System machine, MTS Systems Corporation, Eden Prairie, MN, USA.
The radial compression strength of the stents was measured by a special chamber, constructed in our laboratory. This chamber permits hydrostatic pressure to be applied to the external surface of the stent. The chamber was ported to a manual air pump for pressurization and a sphygmomanometer was used to measure the pressure in the chamber. The pressure difference across the stent wall was increased gradually and the resulting change in the stent diameter was measured. Five samples were tested for each point, for both mechanical property measurements.
RESULTS AND DISCUSSION
The morphology of PLA/dexamethasone lms
The lm structures created from the diluted and concentrated solutions are termed as 'A' and 'B' , respectively. ± C, compared with the corresponding neat matrix lms, L-PLLA and H-PLLA. The melting points of these lms and their degree of crystallinity are presented in Table 1 . Large spherulites (50-100 ¹m) are observed for the L-PLLA lm, as can be expected for a highly crystalline polymer (53.6 %C ). The H-PLLA lm is less crystalline than the L-PLLA one (41.4 %C ) and its spherulites are relatively small (less than 10 ¹m). The structure and crystallinity differences of these polymers result mainly from the molecular weight difference. While the relatively short L-PLLA chains (i.v. D 1:0 dl g ¡1 , corresponding to approximately 130 kD) are likely to crystallize, the long H-PLLA chains (i.v. D 3:6 dl g ¡1 , corresponding to approximately 380 kD) is more dif cult for crystallization. The melting temperature of the H-PLLA lm is higher than that of L-PLLA, probably due to the existence of 'larger' , i.e. more 'perfect' crystals. It should be mentioned that in order to observe the H-PLLA structure, a different degree of polarization was used, and as a result the H-PLLA lms appear with a dark background.
Large rectangular DM crystals (50-300 ¹m) are observed on the surface of both PLLA(A) lms. These crystals can be observed without a polarizer. In both cases, the structure of the polymer lm (below the DM crystals) is similar to that of the neat matrix polymer, indicating that separate crystallization processes probably occur for PLLA and DM at different drying stages. Each DM crystal is actually composed of smaller crystals, gathered during an advanced crystallization stage. As can be expected for such morphologies, the degree of crystallinity of the A type containing DM PLLA lms (52.2 %C for L-PLLA/ DM(A)) and 38.2 %C for H-PLLA/DM(A) are very similar to these of the neat PLLA lms (53.6 %C for L-PLLA and 41.4 %C for H-PLLA). LM observations of B type PLLA/DM lms show a difference in structure, compared to that of the neat matrix polymers. Most of the DM is located within the PLLA lm and only a small part (less than 10%) is located on the surface. Although a polarizer was used, the polymer characteristic features within the L-PLLA/DM(B) lm almost cannot be observed, probably due to distribution of the drug within the polymer lm, disturbing the birefringence effects. Since the degree of crystallinity of this lm is also high (52.0 %C ) and similar to that of the neat L-PLLA (53.6 %C ), it can be assumed that a the L-PLLA lm is also arranged in a spherulitic structure. However, the spherulites of the PLLA within the L-PLLA/DM(B) lm are probably smaller that those of the neat L-PLLA lm. A similar morphology, where most of the DM is dispersed within the polymer matrix, is observed also for the H-PLLA/DM(B) lm. In this case the polymer structure can be observed, due to the relatively high degree of polarization. It appears that the spherulites of the PLLA within the H-PLLA/DM(B) lm are similar to those building the neat H-PLLA lm. The next chapter will elucidate that in order to incorporate the drug in the polymer lm, the two components should crystallize in parallel. Interestingly, for both PLLAs the melting temperature is not affected by DM incorporation in the lm ( Table 1 ), indicating that the DM does not affect the PLLA crystal' s 'size' . Similar morphologies were observed for the corresponding lms containing 3, 5, and 10 wt% DM within the PLLA matrix. In order to better understand the effect of the matrix polymer structure on the DM distribution, PDLLA based lms were prepared. The two basic types of solutions, diluted and concentrated, yielded the A and B lm types, respectively, as shown in Fig. 2 . The PDLLA matrix is amorphous and therefore does not show any typical structure. These morphology studies suggest that the DM mode of dispersion depends mainly on the starting solution and derived parameters (to be discussed below). In the content of this study, the type of poly-lactide affects the polymer morphology, but has a minor effect on the drug distribution in it. The chemical structure of DM is different than that of PLLA and therefore, for the B type lms based on semicrystalline matrix, most of the DM is probably located around the PLLA spherulites, in amorphous domains. For the B type lms based on semicrystalline matrix, the DM crystals are located within the amorphous regions of a semicrystalline polymer, around the spherulites. A ner DM dispersion is obtained within the amorphous PDLLA matrix, due to absence of crystalline structure features, i.e. the DM is not 'directed' to certain domains within the matrix polymer.
Structuring of solution-cast PLA /drug lms
As previously shown, two extreme structures were created: (a) a polymer lm with large DM crystals located on its surface; and (b) a polymer lm with small drug crystals and particles located within the bulk. The process of lm creation during solvent drying was studied to elucidate the structures created and to understand how the various processing parameters affect the lm morphology. Inverted LM micrographs of various points during A and B L-PLLA/DM lm formation are presented in Figs 3 and 4 , respectively. The polymer crystallization process could not be observed via inverted LM, and therefore, polarized compound LM was used to complete the study. The A type PLLA /DM lm formation process is as follows: (a) Nucleation of DM particles on the solution surface (Fig. 3a) . Since the highest rate of solvent evaporation is obtained near the solution / air interface, the primary drug nucleation occurs there. In this stage the solution is diluted.
(b) The concentration of the nuclei increases in parallel to their growth. Hence, many 1-10 ¹m particles and aggregates are observed (Fig. 3b) . The polymer solution is less diluted in this stage. (c) The DM particles segregate, due to inter-particle interactions and crystallization of selected sites, to form ordered shapes (Fig. 3c) . The polymer solution is relatively viscous, since most of the solvent has already been evaporated.
(d) The DM particles are merged to form large rectangular and hexagonal crystals (Fig. 3d) . A spherulitic structure is observed beneath, within the gel-like solution. PLLA crystallization probably started during stage c, at least near the surface where the solvent evaporation rate is relatively high. However, lamellae or very small spherulites cannot be observed via polarized LM, due to lack of birefringence effects. Therefore, the polymer structure was not observed before stage d.
(e) Final drug crystals of characteristic dimensions of 50-300 ¹m are obtained.
The B type PLLA /DM lm formation process is as follows:
(a) Nucleation of DM particles in a very viscous solution and also on its surface. The L-PLLA starts its crystallization (Fig. 4a) .
(b) The DM particles grow, in parallel to the polymer crystallization. Many 1 -10 ¹m particles are observed (Fig. 4b) .
(c) Segregation of DM particles within the viscous medium of the crystallizing polymer (Fig. 4c) . The PLLA spherulites are relatively big and the DM particles migrate to the amorphous domains, around the spherulites and tend to accumulate there.
(d) A semi-network of DM crystals is created in the amorphous domains of the semi-crystalline PLLA matrix (Fig. 4d1) . A higher magni cation (Fig. 4d2 ) indeed shows the rounded shape 'spherulitic features' of the matrix polymer.
Hence, it is suggested that in order to obtain an A type polymer/ drug lm, where the drug is located on the surface of the polymer, both components need to be fully dissolved in a common solvent. A relatively low molecular weight drug tends to crystallize before the high molecular weight polymer. Therefore, during a slow evaporation process, drug nucleation occurs on the surface of the solution, where the highest drying rate is obtained. This stage is accompanied by diffusion of DM molecules from the solution to its surface and skin formation. A later polymer core formation occurs in parallel, to further drug particle merging and crystallization on its surface. In contrast, in order to obtain a B type polymer/ drug lm, where the drug is distributed within the polymer, a relatively concentrated solution must be used, i.e. the polymer solution contains ne drug particles not totally dissolved. Thus, there is over saturation of drug within the solution. After casting, parallel crystallization of both drug and polymer occurs, due to the relatively rapid drying. Since the nature of the drug is different than that of the matrix polymer, the drug particles migrate to the amorphous domains of the crystallizing polymer, where they segregate to form a semi-network structure within the matrix polymer. The concentrated solution contains DM particles rather than molecules, which diffuse more slowly. Therefore, a DM core formation is not favored. In order to further examine the effect of solvent evaporation rate on the lm morphology, a diluted L-PLLA/DM solution was cast and dried relatively rapidly. Drug nuclei appeared on the solution surface, but most of the DM crystallization occurred in a gel-like concentrated solution. As a result, a structure similar to that of the B type lm was created. It is thus suggested that the kinetics of solution drying plays a major role in the DM mode of dispersion in a polymer lm. The opposite process of starting with a concentrated solution and obtain an A type morphology does not occur, even when the drying rate is extremely slow. The relatively slow diffusion rate of DM particles in a viscous medium probably does not enable drug crystal formation on the surface of a growing polymer lm.
The net effect of DM re-crystallization on morphology was investigated at dilute and concentrated solution conditions, observing the obtained structure by SEM. The as-received DM powder consists of particles of 0.1-3 ¹m, partially aggregated (Fig. 5a, b) . Re-crystallization of DM from dilute solution leads to formation of large rectangular crystals (Fig. 5c ). It appears that these crystals are composed of well packed, small primary particles, similar to those of the as-received powder. These tend to merge to large, well arranged structures, due to the slow drying process. It is thus suggested that the rectangular shapes are probably a tertiary structure. In contrast, re-crystallization of DM from concentrated over-saturated DM solution, leads to formation of a structure similar to the original one. Hence, these SEM observations show that the DM distribution within a PLLA lm is determined mainly by the kinetics of drug re-crystallization, whereas the polymer chain structure and morphology have a minor effect on the DM distribution. The latter have a signi cant effect on the lm properties.
LM observations of the lms enable one to elucidate the lm structure. However, a better view of DM dispersion within the B type lm and its particles size could not be observed via LM. Therefore, the morphology of these lms was also studied by electron microscopy. TEM and HRSEM micrographs of H-PLLA/DM(B) lm are presented in Fig. 6 . DM in the form of small rectangular shapes (1 -5 ¹m) appear in addition to small particles (less than 1 ¹m), within the whole cross section area of the lm (Fig. 6a) . This indicates the partial formation of the DM tertiary structure, in spite of the relatively fast drying. The features of the spherulitic PLLA cannot be observed, due to their low contrast. HRSEM micrograph of the cryogenically fractured surface of the lm indicates a poor PLLA-DM interphase adhesion. The chemical nature of the DM is aromatic while that of the PLLA is aliphatic. Therefore, the PLLA does not tend to 'wet' DM, resulting in poor polymer/ drug interphase. The PLLA contains ester groups and each DM molecule contains two carbonyl and three hydroxyl groups. Therefore, speci c strong interactions, namely hydrogen bonds, could have been formed between the carbonyl oxygens in the PLLA chains and the hydroxyl hydrogens in the DM. However, in this system since DM contains both groups, carbonyls and hydroxyls, these strong intermolecular interactions are probably created between adjacent DM molecules and particles, leading to strong DM segregation during lm drying.
To conclude this part, both kinetic parameters of lm formation process and thermodynamic parameters of the system' s components affect the lm morphology. The rate of solvent evaporation and the resulting rate of drug and polymer crystallization have a signi cant effect on the drug distribution and its structure. Solubility effects of the system components determine the nature of the starting solution and therefore affect diffusion processes during drying. Interestingly, PLLA /hydrocortisone and PLLA /curcumin lms, prepared from dilute and concentrated solutions, also showed the A and B structures, respectively. This indicates that the methods of structuring demonstrated in this research, are general.
Mechanical properties in tension
Stress -strain curves of H-PLLA and L-PLLA based lms are presented in Fig. 7 . The measured maximal tensile strength (at break), elastic modulus and maximal strain (at break) are presented in Table 2 . It should be noticed that the treated lms are relatively brittle and their tensile failure occurs at or slightly beyond the yield stress. Therefore the yield stresses and strains are very similar to the maximal stresses and strains, respectively. The untreated as-cast PLLA lms are ductile and have relatively low strength and stiffness (Fig. 7a) . Heat treatment at T > T g results in increase in strength, stiffness and brittleness. One of our studies [20] showed that this occurs due to further crystallization and evaporation of solvent residues. The mechanical properties of a polymer/ drug lm are determined by the lm composition, the polymer's chain structure and its morphology and the drug distribution. The neat H-PLLA is stronger and tougher than L-PLLA, probably due to the higher molecular weight. It should be recalled that the L-PLLA treated lm exhibits 53.6 %C, while the H-PLLA treated lm is less crystalline (41.4 %C, Table 1 ). Hence, the crystallinity effect is not strong enough to compensate for the molecular weight effect; as a result, the more crystalline L-PLLA is weaker than the less crystalline H-PLLA. The chance of brittle failure is decreased by raising molecular weight, which increases brittle strength, and reduces degree of crystallinity [21] . Therefore, in addition to their better strength and stiffness, the H-PLLA lms are more ductile than the L-PLLA. Also, polymers with smaller, ner-textured spherulites tend to fail at relatively high strains, while those with large, coarse spherulites often fail by brittle fracture between spherulites at low strains. Hence, the better ductility of the H-PLLA is obtained due to differences in molecular weight, %C, and the polymer texture.
In general, incorporation of DM to H-PLLA or L-PLLA decreases the strength, modulus and maximal strain (Fig. 7b, c and Table 2 ). As previously mentioned, the treated PLLA is relatively brittle and its tensile failure occurs at or slightly beyond the yield stress. The change in ductility due to addition of the drug is not signi cant. However, it seems that in the B type lms, failure occur below the yield point. In the A type lms, the DM is located on the surface of the PLLA matrix, the polymer structure is very similar to that of the neat PLLA and therefore, the changes in mechanical properties are relatively small. The poor quality of the layers close to the PLLA-DM interphase is probably responsible to these changes. In contrast, in the B type lms, the DM is located within PLLA. As a result, for both, H-PLLA and L-PLLA, the deterioration of mechanical properties due to DM incorporation is more signi cant than in A type lm. The DM molecules consist of a four-ring planar structure and therefore, could be expected to function as a stiff organic ller, increasing stiffness and strength. However, the totally different nature of these components, and the lack of interactions between them, contribute to a poor interphase adhesion and results in deterioration in mechanical properties. Interestingly, deterioration of mechanical properties due to drug incorporation is more signi cant for L-PLLA lm than for the H-PLLA one, especially in the B type lms (Table 2) . It is thus suggested, that the relatively large amount of amorphous phase and ne spherulitic structure of H-PLLA can better tolerate drug incorporation than the smaller amount of amorphous phase and coarser structure of L-PLLA. Morphological studies of the treated lms containing DM did not show any structural changes after applying tensile stress. This results from the low strains at break of the relatively brittle treated lms (Fig. 7b, c) .
Expandable stents prepared from PLLA-based lms
Tubular stents developed of these lms were investigated. Their radial compression properties are presented in Table 3 . The maximal applied pressure using our radial compression chamber is 200 kPa, therefore higher strength values could not be measured. In general, the H-PLLA based stents are stronger than the L-PLLA base ones. They can endure a radial compression pressure of at least 200 kPa without exhibiting any deformation. The L-PLLA stents start to deform at 138 kPa and they break at 158 kPa. They exhibit a small elastic deformation before showing a brittle failure. Incorporation of DM in the lm results in reduction in the stent' s radial compression strength and it starts to deform at lower pressure. However, both stent types, H-PLLA and L-PLLA can serve as conduit support structures (stents etc.), since their initial radial compression strengths are at least fty times higher than the required values. The tensile mechanical properties of a polymer are more sensitive to poor polymer-ller interphase adhesion than compression properties. Therefore the stent' s compression strength can better tolerate drug incorporation than the tensile mechanical properties of the lm. The H-PLLA based lm is stronger and more ductile than the L-PLLA lm. It can better accommodate drug incorporation on the lm surface and also in bulk. 
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In addition, the mechanical properties of the H-PLLA based stents are better than these of the L-PLLA based ones. Therefore H-PLLA stents are more applicable for supporting various body conduits and were chosen for further studies. After serving for a certain period of time in vivo, they will partially degrade and probably show lower mechanical properties, similar to the initial mechanical properties of the L-PLLA stents.
As mentioned before, bioresorbable lms can serve simultaneously as anatomic support structures and as drug delivery platforms. One of our recently reported studies is an in vitro study of these PLLA /dexamethasone lms and the support devices (stents) prepared from these lms [20] . It focuses on the mechanical properties of the lms and the stents. The morphology, degradation and erosion processes and the polymer's initial molecular weight have signi cant effects on the resulting properties. The DM release from these lms has also been studied. In general, during exposure to an aqueous solution a linear accumulative DM release pro le was obtained for the A type lms, throughout the 24 weeks of study. The B type lms showed a linear accumulative release of DM for 12 weeks and then the rate of release decreased gradually with time. The DM release from the A type lm was faster than that from the B type lm. The release kinetics and a mathematical model describing the effects of diffusion and degradation processes will be reported in a separate manuscript.
SUMMARY AND CONCLUSIONS
Bioresorbable PLLA lms containing Dexamethasone were prepared through solution processing accompanied by a post-preparation isothermal heat treatment. The effect of lm processing parameters and components on its morphology and mechanical properties was studied. A model describing the structuring of these lms was suggested.
The solvent evaporation rate determines the kinetics of drug and polymer crystallization and thus, the drug mode of dispersion in the lm. The polymer chain structure and its morphology has a minor effect on the drug distribution. Solubility effects in the starting solution affect the post-casting diffusion processes, occuring in parallel to the drying step. In general, two lm structures were obtained: (a) A polymer lm with large drug tertiary shapes located on its surface. This structure, derived from diluted solution, was obtained due to prior drug nucleation and growth on the polymer solution surface. This skin formation is accompanied by a later polymer core formation. (b) A polymer lm with small drug particles and crystals distributed within the bulk. This structure, derived from concentrated solution, is obtained due to drug nucleation and segregation within a dense polymer solution. Solidi cation of drug and polymer occurred in parallel. The drug is located is amorphous domains of a semicrystalline matrix, around the spherulites.
The mechanical properties of the PLLA lm are determined by the polymer's molecular weight, morphological features and the post-preparation heat treatment. Incorporation of drug in the PLLA lm decreases its strength, modulus and ductility. The mechanical properties deterioration due to drug incorporation is more signi cant for the B type lms than for the A ones. The former contains larger, poor polymer-drug interphase area. H-PLLA can better tolerate drug incorporation than L-PLLA, due to its lower degree of crystallinity and ner spherulitic texture.
Support structures (stents) developed from these lms demonstrated good mechanical properties. The stent radial compression strength is determined mainly by the polymer structure. Drug incorporation has a minor effect on the stent' s strength.
